E-mail: bd@sidmexinovia.com
Telefone: +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Acogenib 250 mg Tablet
Manufacturer/Marketed By : Accord Pharma
$66.86 $40.11
Acogenib 250 mg Tablet is an effective treatment option for adults diagnosed with non-small cell lung cancer (NSCLC) that has metastasized, particularly in patients harboring mutated EGFR genes who have...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
Gefitinib 250 mg
Active Pharmaceutical Ingredient
Acogenib 250 mg Tablet
US$ 66,86
US$ 40,11
Acogenib 250 mg Tablet is an effective treatment option for adults diagnosed with non-small cell lung cancer (NSCLC) that has metastasized, particularly in patients harboring mutated EGFR genes who have not previously undergone cancer therapy. This targeted therapy works by inhibiting the growth of cancer cells, ultimately slowing disease progression and improving patient outcomes. It is crucial to note that Acogenib is not recommended for children or adolescents, as its safety and efficacy in these populations have not been established. Patients may experience side effects, and monitoring by a healthcare professional is essential to manage any adverse reactions effectively. As with any anti-cancer medication, discussing the full range of potential risks and benefits with a healthcare provider is vital. Acogenib offers a promising option for eligible patients seeking to combat advanced NSCLC, making it an important addition to the oncology landscape. If you're considering Acogenib as part of your treatment plan, consult your oncologist to ensure it aligns with your specific health needs.
Active Pharmaceutical Ingredient
Usos
• Acogenib 250 mg tablet is primarily indicated for the treatment of non-small cell lung cancer (NSCLC). This type of lung cancer affects a considerable number of cells in the lungs, making effective treatment essential. By targeting specific pathways involved in cancer cell growth, Acogenib 250 mg tablet helps manage the disease. It is often utilized in patients who have shown resistance to other treatments.
• In patients with advanced non-small cell lung cancer, Acogenib 250 mg tablet can provide an important therapeutic option. This medication works by inhibiting certain proteins that promote cancer cell proliferation. By doing so, Acogenib 250 mg tablet can help slow disease progression and improve patient outcomes. It is commonly prescribed when other lines of treatment have been exhausted.
• Acogenib 250 mg tablet may be used as part of a combination therapy approach for non-small cell lung cancer. When used alongside other medications, it can enhance overall treatment efficacy. The synergistic effects of Acogenib 250 mg tablet with other agents can lead to better management of the disease. Oncologists often consider this medication for patients requiring a more aggressive treatment strategy.
• For individuals diagnosed with non-small cell lung cancer, Acogenib 250 mg tablet offers a targeted treatment solution. This medication is formulated to specifically address the unique characteristics of NSCLC. By utilizing Acogenib 250 mg tablet, healthcare providers aim to improve the quality of life for patients. It is particularly beneficial for those who may have limited options due to the nature of their cancer.
Benefícios
Gefitinib Tablet 250 mg inhibits a protein called epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By inhibiting this protein, Acogenib Tablet may help to slow the progression of cancer.
Acogenib 250 mg may help reduce the severity of cancer-related symptoms, such as pain and fatigue, which can improve a patient's overall quality of life.
Gefitinib Tablet 250 mg may be used in combination with other cancer treatments, such as chemotherapy, to improve their effectiveness.
Efeitos colaterais
As with all medicines, Acogenib 250 mg Strip may cause some side effects. If you experience any of these side effects, you should contact your doctor or health care professional as soon as possible. Your doctor may be able to suggest ways in which these side effects can be managed or the severity of them reduced.
Efeitos colaterais mais comuns
• Tremor
• Hypertension
• Headache
• Increased Potassium levels in the blood
• Hypertension
• Gastrointestinal problems
• Abnormal Growth of Hair
Efeitos colaterais comuns
• Liver Damage
• Seizures
• Infection
• Kidney Damage
• Memory Problems
• Vision Problems
• Sleeplessness
Como usar
It is recommended to consume Acogenib 250 mg Strip with or without food. Be sure to swallow the tablet whole with a complete glass of water. Avoid crushing, chewing, or opening the tablet. In case you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and adhere to your regular dosing schedule. Remember not to take two doses simultaneously to compensate for a missed dose.
Conselhos de segurança
• Alcohol: The use of alcohol is generally not recommended while taking Anti-cancer Drug Acogenib as it may increase the risk of liver damage. It is advisable to either abstain from alcohol or limit your alcohol intake while taking any medication.
• Kidney: Acogenib 250 mg Tablet is considered safe for patients with mild to moderate kidney disease and no dose adjustment of Acogenib 250 mg is required. However, people with severe kidney disease are advised not to take Acogenib Tablet Tablet. To ensure the safety and effectiveness of your treatment, it is important to have an open discussion with your doctor about all your medical conditions and medications.
• Breastfeeding: It is not advisable to breast-feed while taking Acogenib Tablet as this may cause harm to the baby. Acogenib 250 mg Tablet can pass into breast milk and cause adverse effects. If you are currently breastfeeding and using Gefitinib Tablet 250 mg, it is important to discuss with your doctor the potential risks and benefits of continuing to breastfeed. Your doctor will help you make the decision that is best for you and your baby.
• Liver: Acogenib 250 mg Tablet is considered safe for patients with mild to moderate liver disease, and there is no need to adjust the dose of Gefitinib Tablet 250 mg. However, people with severe liver disease should not use Anti-cancer Drug Acogenib. It is important to have an open discussion with your doctor about your medical conditions and medications to ensure that the treatment plan is appropriate for you.
• Pregnancy: Acogenib 250 mg Tablet may be unsafe during pregnancy as animal studies suggest that it may harm the developing fetus. However, if you are pregnant or planning to get pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Acogenib 250 mg Strip while pregnant. Your doctor will be able to help you make the decision that is best for you and for the health of your baby.
• Driving: Acogenib 250 mg Tablet may cause dizziness, drowsiness, and problems with concentration and coordination, which may impair your ability to drive a vehicle safely. It is important that you follow your doctor's instructions and take the necessary measures, such as avoiding driving or operating heavy machinery, if you experience any of these side effects caused by Gefitinib Tablet 250 mg.
Isenção de responsabilidade
A Sidmex Inovia se esforça para fornecer informações precisas e confiáveis; no entanto, todo o conteúdo deste site, incluindo descrições e composições de produtos, tem caráter meramente informativo e não deve ser considerado um substituto para aconselhamento, diagnóstico ou tratamento médico profissional.
Recomenda-se aos usuários que consultem um profissional de saúde qualificado antes de tomar qualquer decisão médica. As informações fornecidas não devem ser usadas para autodiagnóstico ou automedicação.
Todos os produtos listados destinam-se estritamente a consultas B2B e em grandes quantidades. A Sidmex Inovia não promove o uso direto pelo consumidor e visa apoiar, e não substituir, a relação entre o profissional de saúde e o paciente.
Os nomes de produtos, marcas comerciais e marcas pertencem aos seus respectivos proprietários, e seu uso não implica qualquer afiliação ou endosso. A Sidmex Inovia não se responsabiliza por quaisquer consequências decorrentes do uso das informações fornecidas neste site.